The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
A Proangiogenic Signature Is Revealed in FGF-Mediated Bevacizumab-Resistant Head and Neck Squamous Cell Carcinoma
Open accessPublished version of a preprint
Abstract
Resistance to antiangiogenic therapies is a critical problem that has limited the utility of antiangiogenic agents in clinical settings. However, the molecular mechanisms underlying this resistance have yet to be fully elucidated. In this study, we established a novel xenograft model of acquired resistance to bevacizumab. To identify molecular changes initiated by the tumor cells, we performed human-specific microarray analysis on bevacizumab-sensitive and -resistant tumors. Efficiency analysis identified 150 genes upregulated and 31 genes downregulated in the resistant tumors. Among angiogenesis-related genes, we found upregulation of fibroblast growth factor-2 (FGF2) and fibroblast growth factor receptor-3 (FGFR3) in the resistant tumors. Inhibition of the FGFR in the resistant tumors led to the restoration of sensitivity to bevacizumab. Furthermore, increased FGF2 production in the resistant cells was found to be mediated by overexpression of upstream genes phospholipase C (PLCg2), frizzled receptor-4 (FZD4), chemokine [C-X3-C motif] (CX3CL1), and chemokine [C-C motif] ligand 5 (CCL5) via extracellular signal-regulated kinase (ERK). In summary, our work has identified an upregulation of a proangiogenic signature in bevacizumab-refractory HNSCC tumors that converges on ERK signaling to upregulate FGF2, which then mediates evasion of anti-VEGF therapy. These findings provide a new strategy on how to enhance the therapeutic efficacy of antiangiogenic therapy. Implications: Novel xenograft model leads to the discovery of FGF as a promising therapeutic target in overcoming the resistance of antiangiogenic therapy in HNSCC. Mol Cancer Res; 11(12); 1585–96. ©2013 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Using patient material and mouse/human xenograft models, PLCγ2 was revealed to be an overexpressed upstream mediator, among other factors resulting in ERK signaling, that induced increased FGF-mediated bevacizumab resistance in head and neck squamous cell carcinoma (154).”
From The role of PLCγ2 in immunological disorders, cancer, and neurodegeneration (2021) · cites this paper as [154]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
Fibroblast growth factor signalling: from development to cancer
Turner, N. C., & Grose, R. P. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2780 · Cited by 2,768
Yang, J. C., Haworth, L. R., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,704
Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
A systems biology approach for pathway level analysisPreprint
Drăghici, S., Khatri, P., Tarca, A. L., Amin, K., Done, A., Voichiţa, C., Georgescu, C., & Romero, R. J. (2007) · Genome Research · doi:10.1101/gr.6202607 · Cited by 1,263
Pepper, M. S., Ferrara, N., Orci, L., & Montesano, R. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(92)92277-5 · Cited by 856
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., Fuh, G., Gerber, H.-P., & Ferrara, N. (2007) · Nature Biotechnology · doi:10.1038/nbt1323 · Cited by 849
Cited by
Sorted by citations
Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
Haibe, Y., Kreidieh, M., Hajj, H. E., Khalifeh, I. M., Mukherji, D., Temraz, S. N., & Shamseddine, A. I. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00221 · Cited by 430
Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics
Abdalla, A. M. E., Xiao, L., Ullah, M. W., Yu, M., Ouyang, C., & Yang, G. (2018) · Theranostics · doi:10.7150/thno.21674 · Cited by 240
Incio, J., Ligibel, J. A., McManus, D. T., Suboj, P., Jung, K., Kawaguchi, K., Pinter, M., Babykutty, S., Chin, S. M., Vardam, T. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aag0945 · Cited by 222
The Great Escape; the Hallmarks of Resistance to Antiangiogenic Therapy
B, J. R. V. B., Nowak-Sliwinska, P. M., Huijbers, E. J. M., Thijssen, V. L., & Griffioen, A. W. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.010215 · Cited by 211
Cancer combination therapies by angiogenesis inhibitors; a comprehensive review
Ansari, M. J., Bokov, D., Markov, A., Jalil, A. T., Shalaby, M. N., Suksatan, W., Chupradit, S., AL-Ghamdi, H. S., Shomali, N., Zamani, A., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00838-y · Cited by 197
Adachi, Y., Kamiyama, H., Ichikawa, K., Fukushima, S., Ozawa, Y., Yamaguchi, S., Goda, S., Kimura, T., Kodama, K., Matsuki, M., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2426 · Cited by 169
Mechanisms of Action of Novel Drugs Targeting Angiogenesis-Promoting Matrix Metalloproteinases
Fields, G. B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01278 · Cited by 140
Lorenc, P., Sikorska, A., Molenda, S., Guzniczak, N., Dams‐Kozlowska, H., & Florczak, A. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117585 · Cited by 142
FGF/FGFR signaling pathway involved resistance in various cancer types.
Zhou, Y., Wu, C., Lu, G., Hu, Z., Chen, Q., & Du, X. (2020) · Journal of Cancer · doi:10.7150/jca.40531 · Cited by 117
The role of PLCγ2 in immunological disorders, cancer, and neurodegeneration
Jackson, J. T., Mulazzani, E., Nutt, S. L., & Masters, S. L. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100905 · Cited by 113
Mountzios, G., Rampias, T. N., & Psyrri, A. K. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu143 · Cited by 109
Targeting endothelial permeability in the EPR effect
Lahooti, B., Akwii, R. G., Zahra, F. T., Sajib, M. S., Λάμπρου, Μ., Alobaida, A., Lionakis, M. S., Mattheolabakis, G., & Mikelis, C. M. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.039 · Cited by 114
Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs
Montemagno, C., & Pagès, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00584 · Cited by 100
FGF/FGFR-Dependent Molecular Mechanisms Underlying Anti-Cancer Drug Resistance
Szymczyk, J., Służalska, K. D., Materla, I., Opaliński, Ł., Otlewski, J., & Zakrzewska, M. (2021) · Cancers · doi:10.3390/cancers13225796 · Cited by 92
Li, D., Xie, K., Zhang, L., Yao, X., Li, H., Xu, Q., Wang, X., Jiang, J., & Fang, J. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.04.036 · Cited by 82
Quan, L., Ohgaki, R., Hara, S., Okuda, S., Wei, L., Okanishi, H., Nagamori, S., Endou, H., & Kanai, Y. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01762-0 · Cited by 74
Sekiguchi, K., Ito, Y., Hattori, K., Inoue, T., Hosono, K., Honda, M., Numao, A., Amano, H., Shibuya, M., Unno, N., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-43185-8 · Cited by 71
Obesity and Cancer: An Angiogenic and Inflammatory Link
Fukumura, D., Incio, J., Shankaraiah, R. C., & Jain, R. K. (2016) · Microcirculation · doi:10.1111/micc.12270 · Cited by 69
Role of bFGF in Acquired Resistance upon Anti-VEGF Therapy in Cancer
Zahra, F. T., Sajib, M. S., & Mikelis, C. M. (2021) · Cancers · doi:10.3390/cancers13061422 · Cited by 71
Dovitinib (CHIR258, TKI258): Structure, Development and Preclinical and Clinical Activity
Porta, C., Giglione, P., Liguigli, W., & Paglino, C. (2015) · Future Oncology · doi:10.2217/fon.14.208 · Cited by 64
Li, J., Liu, X., Zang, S., Zhou, J., Zhang, F., Sun, B., Qi, D., Li, X., Kong, J., Jin, D., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.08.030 · Cited by 62
Ichikawa, K., Miyano, S. W., Minoshima, Y., Matsui, J., & Funahashi, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-59853-z · Cited by 58
FGFR signaling regulates resistance of head and neck cancer stem cells to cisplatin
McDermott, S., Rodriguez-Ramirez, C., McDermott, S., Wicha, M. S., & Nor, J. E. (2018) · Oncotarget · doi:10.18632/oncotarget.25358 · Cited by 55
Unraveling the molecular mechanisms between inflammation and tumor angiogenesis.
Zhou, W., Yang, L., Nie, L., & Lin, H. (2021) · PubMed Central · Cited by 51
Hu, M., Hu, Y., He, J., & Baolan, L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147374 · Cited by 49
Jiang, X. Y., Liu, J., Li, S., Jia, B., Huang, Z., Shen, J., Luo, H., & Zhao, J. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02978-w · Cited by 47
Frizzled receptors (FZDs) in Wnt signaling: potential therapeutic targets for human cancers
Liu, H., Sun, X., Xiu, S., Zhang, X., Wang, Z., Gu, Y.-L., Yi, C., Liu, J.-Y., Dai, Y.-S., Xia, Y., et al. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01270-3 · Cited by 40
Yamauchi, M., Ono, A., Amioka, K., Fujii, Y., Nakahara, H., Teraoka, Y., Uchikawa, S., Fujino, H., Nakahara, T., Murakami, E., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00390-x · Cited by 40
Realizing Cancer Precision Medicine by Integrating Systems Biology and Nanomaterial Engineering
Joo, J. I., Choi, M., Jang, S., Choi, S. R., Park, S., Shin, D., & Cho, K. (2020) · Advanced Materials · doi:10.1002/adma.201906783 · Cited by 35
Therapeutic Targeting of FGFR Signaling in Head and Neck Cancer
Wang, Z.-C., & Anderson, K. S. (2022) · Cancer Journal · doi:10.1097/ppo.0000000000000615 · Cited by 28
Carbone, C., Tamburrino, A., Piro, G., Boschi, F., Cataldo, I., Zanotto, M., Mina, M. M., Zanini, S., Sbarbati, A., Scarpa, A., et al. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000301 · Cited by 34
Vafopoulou, P., & Kourti, M. (2022) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2022.08 · Cited by 31
Nuclear basic fibroblast growth factor regulates triple-negative breast cancer chemo-resistance
Li, S., Payne, S., Wang, F., Claus, P., Su, Z., Groth, J., Geradts, J., de Ridder, G., Álvarez, R., Marcom, P. K., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0590-3 · Cited by 31
Oyesanya, R. A., Bhatia, S., Menezes, M. E., Dumur, C. I., Singh, K. P., Bae, S., Troyer, D. A., Wells, R. B., Sauter, E. R., Sidransky, D., et al. (2014) · Oncoscience · doi:10.18632/oncoscience.99 · Cited by 29
A novel decoy receptor fusion protein for FGF-2 potently inhibits tumour growth
Li, D., Wei, X., Xie, K., Chen, K., Li, J., & Fang, J. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.282 · Cited by 26
Melaiu, O., Vanni, G., Portarena, I., Pistolese, C. A., Anemona, L., Pomella, S., Bei, R., Buonomo, O. C., Roselli, M., Mauriello, A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043226 · Cited by 26
Eswaran, S., Padavu, M., Kumar, D., & Kabekkodu, S. P. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230816100623 · Cited by 21
Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy
Cao, J., Zhang, Z., Zhou, L., Luo, M., Li, L., Li, B., Nice, E. C., He, W., Zheng, S., & Huang, C. (2023) · MedComm · doi:10.1002/mco2.427 · Cited by 19
Jia, T., Vaganay, E., Carpentier, G., Coudert, P., Gonzalez, V. G., Manuel, R., Eymin, B., Coll, J., & Ruggiero, F. (2020) · Matrix Biology · doi:10.1016/j.matbio.2020.07.001 · Cited by 19
Ban, M. J., Byeon, H. K., Yang, Y. J., An, S.-J., Kim, J. W., Kim, J. H., Kim, D., Yang, J., Kee, H. J., & Koh, Y. W. (2018) · Cancer Science · doi:10.1111/cas.13839 · Cited by 18
Wang, X., Niu, X., Zhang, X., Zhang, Z., Gao, X., Wang, W., & Yuan, Z. (2021) · Journal of Materials Chemistry B · doi:10.1039/d1tb00515d · Cited by 18
Lin, Y., Lin, F., Zhang, Z., Peng, L., Yang, W., Yang, M., Luo, B., Wu, T., Li, D., Li, X., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.74574 · Cited by 16
Shu, C., Sun, P., Xie, H., Huang, W., Qi, J., & Ma, Y. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s237182 · Cited by 15
Far beyond anti-angiogenesis: Benefits for anti-basicFGF therapy in cancer
Li, C., Kuang, K., Du, J., Eymin, B., & Jia, T. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2022.119253 · Cited by 15
Yang, M., Yu, X., Li, X., Luo, B., Yang, W., Lin, Y., Li, D., Gan, Z., Xu, J., & He, T. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1024-9 · Cited by 15
Gökmen‐Polar, Y., Goswami, C. P., Toroni, R. A., Sanders, K. L., Mehta, R. J., Sirimalle, U., Tanasă, B., Shen, C., Li, L., Ivan, M., et al. (2014) · Journal of Cancer · doi:10.7150/jca.8466 · Cited by 13
Giampieri, R., Ziranu, P., Daniele, B., Zizzi, A., Ferrari, D., Lonardi, S., Zaniboni, A., Cavanna, L., Rosati, G., Casagrande, M., et al. (2020) · Cancers · doi:10.3390/cancers12051330 · Cited by 13
Prieto-Fernández, L., Montoro-Jiménez, I., de Luxán‐Delgado, B., Otero‐Rosales, M., Rodrigo, J. P., Calvo, F., Garcia-Pedrero, J. M., & Álvarez–Teijeiro, S. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114502 · Cited by 13
Xu, T., Zeng, X.-W., Wang, X., Yang, L., Luo, G., & Yu, T. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.707066 · Cited by 12
Fibroblast Growth Factor Receptor (FGFR) as a Therapeutic Target in Lung and Head and Neck Cancer
Chae, Y. K., Pai, S. G., Sun, P., Costa, R. L. B., Matsangou, M., Agulnik, M., & Giles, F. J. (2016) · American Journal of Hematology / Oncology® · Cited by 9
Pei, W., Zhang, Z., Lin, M., Zhou, B., & Wang, Z. (2020) · Cytokine · doi:10.1016/j.cyto.2020.155022 · Cited by 8
Chen, X., Sun, J., Zhang, L.-P., Liao, X., & Liao, R.-X. (2017) · Oncology Letters · doi:10.3892/ol.2017.6236 · Cited by 8
Luo, D., Kumfu, S., Chattipakorn, N., & Chattipakorn, S. C. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116845 · Cited by 7
WINNER: A network biology tool for biomolecular characterization and prioritization
Nguyen, T. M., Yue, Z., Slominski, R. M., Welner, R. S., Zhang, J. J., & Chen, J. Y. (2022) · Frontiers in Big Data · doi:10.3389/fdata.2022.1016606 · Cited by 7
Hu, M., Hu, Y., Gao, G., Han, Y., Shi, G., & Li, B. (2014) · Thoracic Cancer · doi:10.1111/1759-7714.12202 · Cited by 7
Heublein, S., Pfisterer, J., du Bois, A., Anglesio, M. S., Aminossadati, B., Bhatti, I., Sehouli, J., Wimberger, P., Schochter, F., Hilpert, F., et al. (2023) · Laboratory Investigation · doi:10.1016/j.labinv.2023.100321 · Cited by 6
Patel, V. K., Shirbhate, E., Singh, V. P., Parveen, S., Veerasamy, R., Tiwari, A. K., & Rajak, H. (2025) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266324868250123052818 · Cited by 5
Zhang, L., Deng, Y., Zhang, Y., Liu, C., Zhang, S., Zhu, W., Tang, Y., & Deng, N. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01190 · Cited by 4
RetractedNutrients Lowering Obesity-Linked Chemokines Blamable for Metastasis
Ion, G., Bostan, M., Hardman, W. E., McFarland, M. P., Bleoţu, C., Radu, N., Diaconu, C. C., Mihaila, M. A., Caramihai, M. D., & Hotnog, C. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052275 · Cited by 4
Li, I., Huo, Y., Yang, T., Gunawan, H., Alexandrov, L. B., & Zage, P. E. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2024.208 · Cited by 4
The Role of Inflammatory Cells in Tumor Angiogenesis
Tamma, R., Annese, T., & Ribatti, D. (2022) · Biology of extracellular matrix · doi:10.1007/978-3-030-99708-3_14 · Cited by 2
Tanaka, T., Takehara, K., Usami, T., Ishikawa, M., Kondo, E., Kagabu, M., Hirabayashi, K., Matsumura, N., Sato, S., Nishimura, M., et al. (2025) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2025.101740 · Cited by 1
Zhang, T., Cui, W., Tang, H., Shen, C., Zhang, Y., Sun, Y., Zhou, Y., Shen, C., Xu, H., Wang, C., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102661 · Cited by 1
Wang, Y., MaoYan, T., Peng, C., Yang, J., Liu, F., Ding, D., Guo, Y., Yu, Y., & Han, F. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116821 · Cited by 2
Crosstalk Mechanisms Following Targeted Therapy in Head and Neck Cancer
Byeon, H. K. (2016) · Korean Journal of Otorhinolaryngology - Head and Neck Surgery · doi:10.3342/kjorl-hns.2016.59.3.181 · Cited by 1
Ghita, I., Piperi, E. P., Atamas, S. P., Bentzen, S. M., Ord, R. A., Dyalram, D., Lubek, J. E., & Younis, R. H. (2022) · Frontiers in Oral Health · doi:10.3389/froh.2022.993638 · Cited by 1
Fibroblast growth factor receptors as therapeutic targets in head and neck squamous cell carcinomas
SenthilKumar, G., Francis, D. M., & Baschnagel, A. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817868-3.00011-1 · Cited by 1
Morbidelli, L., & Donnini, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90190-1.00018-4
Ribatti, D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822803-6.00007-7
Wang, Z., Wang, Z., Deng, L., Wu, X., Liang, Y., & Pei, W. (2024) · Doklady Biochemistry and Biophysics · doi:10.1134/s1607672924600283
Quan, L., Ohgaki, R., Hara, S., Okuda, S., Wei, L., Okanishi, H., Nagamori, S., Endou, H., & Kanai, Y. (2020) · Figshare · doi:10.6084/m9.figshare.13310272
Reimagining VEGF Therapy: The Role of PLCγ2 in Pan-Organ Endothelial Networks
Abouhashem, A. S., Verma, S. S., Faden-McCormack, J., Moqidem, Y. A., Dutta, P., Sen, C. K., & Singh, K. (2026) · Advances in Wound Care · doi:10.1177/21621918261474733
Metadata
- Authors
- Gyanchandani, R., Ortega Alves, M. V., Myers, J. N., & Kim, S.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Authors' Affiliations: Departments of 1Pharmacology and Chemical Biology, and 2 Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; and 3Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas
- Corresponding author
- Kim, Seungwon
- Venue
- Molecular Cancer Research
- Published
- 2013-12-01
- Volume
- 11
- Issue
- 12
- Pages
- 1585-1596
- ISSN
- 1541-7786 (ISSN-L)
- 1557-3125
- PMC
- PMC3955724
- OpenAlex
- W2073944569
- Cited by
- 73
- References
- 44
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 3 · 2023: 8 · 2022: 8 · 2021: 8 · 2020: 15 · 2019: 2 · 2018: 5 · 2017: 2 · 2016: 5 · 2015: 4 · 2014: 5
- FWCI
- 2.09
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Molecular Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- American College of Surgeons
- University of Pittsburgh
- Gladstone Ports Corporation
- National Cancer Institute (L30 CA136371)
- National Institute of Dental and Craniofacial Research (K08DE019201)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Keywords
- bevacizumab resistance, head and neck squamous cell carcinoma, anti-angiogenic therapy, fibroblast growth factor 2, FGFR3, ERK signaling, PLCγ2, FZD4, fractalkine, RANTES, xenograft models, VEGF-independent angiogenesis, therapeutic target
- MeSH terms
- Bevacizumab, Squamous Cell Carcinoma of Head and Neck, Animals, Carcinoma, Squamous Cell, Drug Therapy, Combination, Female, Head and Neck Neoplasms, Humans, Mice, Nude, Neoplasms, Experimental, Neovascularization, Pathologic, Pyrimidines, Gene Expression Regulation, Neoplastic, Fibroblast Growth Factor 2, Drug Resistance, Neoplasm, Angiogenesis Inhibitors, MAP Kinase Signaling System, Xenograft Model Antitumor Assays, Cell Line, Tumor, Protein Kinase Inhibitors, Mice, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
